v3.26.1
Segment disclosures (Tables)
12 Months Ended
Dec. 31, 2025
Veraxa Biotech A G [Member]  
Entity Information [Line Items]  
Schedule of contribute to the assessment of segment performance
               
    For the
years ended
December 31,
 
    2025     2024  
Revenue   23,426     -  
Cost of goods sold     (7,965 )     -  
Gross profit     15,461       -  
                 
General and administrative expenses     (46,922,232 )     (17,095,133 )
Research and development expenses     (10,264,123 )     (6,310,608 )
Sales and marketing expenses     (6,948,456 )     (3,635,658 )
Depreciation and amortization expenses     (2,097,225 )     (1,876,482 )
Operating loss   (66,216,575 )   (28,917,881 )